Aclaris Therapeutics (ACRS) CBO Loerop exercises RSUs and withholds shares

Rhea-AI Filing Summary

Aclaris Therapeutics Chief Business Officer James Loerop reported routine equity compensation activity. On February 3, 2026, 20,875 restricted stock units were converted into an equal number of Aclaris common shares. Each restricted stock unit represents the right to receive one share of common stock.

To cover tax withholding on this vesting, the issuer withheld 5,937 common shares at $3.47 per share, reported under transaction code F. After these transactions, Loerop directly owned 192,260 shares of common stock and 62,625 restricted stock units, which continue to vest in four equal installments on the first four anniversaries of February 3, 2025, subject to continuous service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loerop James

(Last) (First) (Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		M		20,875	A	(1)	198,197	D
Common Stock	02/03/2026		F(2)		5,937	D	$3.47	192,260	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/03/2026		M			20,875	(3)	(3)	Common Stock	20,875	$0	62,625	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

3. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

	/s/ Matthew Rothman, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aclaris Therapeutics (ACRS) report for James Loerop?

Aclaris Therapeutics reported that Chief Business Officer James Loerop had 20,875 restricted stock units convert into common shares on February 3, 2026. These units represented the right to receive one share each of Aclaris common stock upon vesting under the company’s equity plan.

How many Aclaris Therapeutics (ACRS) shares were withheld for taxes in this Form 4?

The filing shows 5,937 Aclaris Therapeutics common shares were withheld at $3.47 per share. This withholding satisfied James Loerop’s tax obligations arising from the vesting and settlement of restricted stock units reported in the same Form 4 transaction.

How many Aclaris Therapeutics (ACRS) shares does James Loerop own after this transaction?

After the reported transactions, James Loerop directly owned 192,260 shares of Aclaris Therapeutics common stock. This figure reflects both the 20,875 shares issued from restricted stock units and the 5,937 shares withheld to cover the related tax obligations.

What Aclaris Therapeutics (ACRS) derivative holdings does James Loerop report?

James Loerop reports holding 62,625 restricted stock units in Aclaris Therapeutics after the transaction. Each restricted stock unit entitles him to receive one share of Aclaris common stock, subject to vesting conditions and continued service under the company’s equity plan.

How do James Loerop’s Aclaris (ACRS) restricted stock units vest over time?

The restricted stock units underlying these transactions vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025. Vesting is conditioned on James Loerop’s continuous service to Aclaris Therapeutics on each applicable anniversary date.

What do the Form 4 transaction codes M and F mean for Aclaris (ACRS)?

In this Aclaris Form 4, code M indicates the conversion of 20,875 restricted stock units into common shares. Code F reflects the issuer’s withholding of 5,937 common shares at $3.47 solely to satisfy James Loerop’s related tax withholding obligations.